A real-world study published in Nature Communications evaluated comparative safety of second-line antihyperglycemic agents in older adults with type 2 diabetes. Kim, Bu, Blacketer and colleagues reported results using observational evidence aimed at clarifying which agents carry different risk profiles in elderly populations. The focus on “second-line” therapy reflects how treatment sequencing can alter safety concerns, particularly in patients with comorbidities and age-related vulnerabilities. The dataset provides clinicians and payers with evidence to inform regimen selection when balancing glycemic control against safety outcomes in older patients.